Gamida Cell Ltd
NASDAQ:GMDA
Relative Value
The Relative Value of one GMDA stock under the Base Case scenario is 0.0712 USD. Compared to the current market price of 0.0184 USD, Gamida Cell Ltd is Undervalued by 74%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
GMDA Competitors Multiples
Gamida Cell Ltd Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
IL |
Gamida Cell Ltd
NASDAQ:GMDA
|
2.7m USD | 1.5 | -0 | -0.4 | -0.4 | ||
US |
Abbvie Inc
NYSE:ABBV
|
281.3B USD | 5.2 | 58.4 | 12.7 | 19.4 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
148.1B USD | 5.3 | 22 | 16.4 | 24.5 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.8B USD | 10.5 | 28.7 | 23 | 24 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
101.7B USD | 7.8 | 25.7 | 17.2 | 18.9 | ||
AU |
CSL Ltd
ASX:CSL
|
133B AUD | 6.2 | 35.4 | 21.4 | 26.6 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.1B USD | 3 | 167.6 | 6.7 | 8.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
45.8B USD | 6.7 | -9.7 | -10.4 | -8.9 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 3.2 | 26.8 | 13.8 | 17.2 | ||
KR |
Celltrion Inc
KRX:068270
|
38.9T KRW | 17.9 | 72.5 | 44.4 | 61.1 |